Nephrology News
Early CRP Response to mRCC Drugs Predicts Survival
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/